Patent: 6,395,487
✉ Email this page to a colleague
Summary for Patent: 6,395,487
| Title: | Method chromosomal rearrangement by consecutive gene targeting of two recombination substrates to the deletion endpoints |
| Abstract: | The present invention involves the creation of defined chromosomal deficiencies, inversions and duplications using Cre recombinase in ES cells transmitted into the mouse germ line. These chromosomal reconstructions can extend up to 3-4 cM. Chromosomal rearrangements are the major cause of inherited human disease and fetal loss. Additionally, translocations and deletions are recognized as major genetic changes that are causally involved in neoplasia. Chromosomal variants such as deletions and inversions are exploited commonly as genetic tools in organisms such as Drosophila. Mice with defined regions of segmental haploidy are useful for genetic screening and allow accurate models of human chromosomal diseases to be generated. |
| Inventor(s): | Bradley; Allan (Houston, TX), Ramirez-Solis; Ramiro (Missouri City, TX), Liu; Pentao (Frederick, MD), Su; Hong (Houston, TX), Zheng; Binhai (Houston, TX) |
| Assignee: | Baylor College of Medicine (Houston, TX) |
| Application Number: | 09/552,219 |
| Patent Claims: | see list of patent claims |
Details for Patent 6,395,487
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | For Injection | 103132 | 06/04/1986 | ⤷ Try a Trial | 2016-06-26 |
| Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | For Injection | 103132 | ⤷ Try a Trial | 2016-06-26 | |
| Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | Injection | 103132 | ⤷ Try a Trial | 2016-06-26 | |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
